# US 8,278,306 B2 · C-met protein kinase inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,278,306 B2
- Document ID: US8278306B2
- Status: Granted
- Kind: B2
- Application number: 13/253,322
- Filed: 2011-10-05
- Published: 2012-03-15
- Granted: 2012-10-02
- Earliest claimed: 2006-05-12
- Assignees: Vertex Pharmaceuticals Incorporated
- Inventors: Jeremy Green; Jingrong Cao; Upul Keerthi Bandarage; Jon H. Come; Craig Marhefka
- Web page: https://patentgrep.com/patent/US8278306B2

## CPC

- C07D 409/04: directly linked by a ring-member-to-ring-member bond
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/08: Vasodilators for multiple indications
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/12: Antihypertensives
- A61P 9/14: Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- A61P 11/06: Antiasthmatics
- A61P 13/12: of the kidneys
- A61P 15/06: Antiabortive agents; Labour repressants
- A61P 15/10: for impotence
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 27/06: Antiglaucoma agents or miotics
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 35/04: specific for metastasis
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 409/14: containing three or more hetero rings
- C07D 417/04: directly linked by a ring-member-to-ring-member bond
- C07D 417/14: containing three or more hetero rings
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Described herein are compounds that are useful as ROCK inhibitors. These compounds, and pharmaceutically acceptable compositions thereof, are useful for treating or lessening the severity of a variety of disorders, including cardiovascular, inflammatory, neurological, or proliferative diseases or disorders.

## Claims

### Claim 1

A compound having the formula:
or a pharmaceutically acceptable salt thereof, wherein:
R1 is halogen —NR2, —OR, —SR, or a C1-4 alkyl;
R2 is hydrogen or C1-3 aliphatic;
each R3 is, independently, hydrogen or a C1-4 alkyl;
X1 is N;
T is a bond or a C1-C6 alkylidene chain, wherein up to two methylene units of T are optionally and independently replaced by —NR′—, —S—, —O—, —C(O)NR′—, —NR′C(O)—, —NR′C(O)O—, —S(O)2NR′—, —NR′S(O)2—, —NR′C(O)NR′—, —OC(O)NR′—, or —NR′S(O)2NR′—;
each R5 is, independently, Ra or halogen;
n is 1 to 3;
each occurrence of Ra is, independently, hydrogen, an optionally substituted moiety selected from a C1-4 alkyl group, a C3-6 cycloalkyl group, a C1-4 haloalkyl group, or a heterocyclic ring selected from morpholino, piperidinyl, or piperazinyl;
each optionally substituted group or ring is optionally substituted with 1-5 substituents independently selected from C1-4 alkyl, C3-6 cycloalkyl, C1-4 haloalkyl, halogen, or —OR″;
each occurrence of R is, independently, hydrogen, a C1-4 alkyl group, a C3-6 cycloalkyl group, —(CH2)1-2Ph, —CH═CHPh, or a C1-4 haloalkyl group;
each occurrence of R′ is, independently, hydrogen or a C1-4 alkyl group; and
each occurrence of R″ is, independently, hydrogen or a C1-4 alkyl group.

### Claim 2 (depends on 1)

The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein R1 is halogen, —NR2, —OR, or an optionally substituted C1-4 alkyl.

### Claim 3 (depends on 2)

The compound according to claim 2 or a pharmaceutically acceptable salt thereof, wherein R1 is C1-4 alkyl.

### Claim 4 (depends on 3)

The compound according to claim 3 or a pharmaceutically acceptable salt thereof, wherein R1 is CH3 or CH2CH3.

### Claim 5 (depends on 2)

The compound according to claim 2 or a pharmaceutically acceptable salt thereof, wherein R1 is halogen.

### Claim 6 (depends on 5)

The compound according to claim 5 or a pharmaceutically acceptable salt thereof, wherein said halogen is fluoro or chloro.

### Claim 7 (depends on 2)

The compound according to claim 2 or a pharmaceutically acceptable salt thereof, wherein R1 is NR2.

### Claim 8 (depends on 7)

The compound according to claim 7 or a pharmaceutically acceptable salt thereof, wherein R1 is NH2, NHCH3, N(CH3)2, NHCH2CH3, or NHCH2Ph.

### Claim 9 (depends on 2)

The compound according to claim 2 or a pharmaceutically acceptable salt thereof, wherein R1 is OR.

### Claim 10 (depends on 9)

The compound according to claim 9 or a pharmaceutically acceptable salt thereof, wherein R1 is OCH3 or OCH2CH3.

### Claim 11 (depends on 1)

The compound according to claim 1, wherein one of -TR5 is at the 3-position.

### Claim 12 (depends on 11)

The compound according to claim 11, wherein -TR5 is chloro, fluoro, —OH, optionally substituted C1-4 alkoxy, —NHS(O)2Ra, —S(O)2NRRa.

### Claim 13

A compound selected from

### Claim 14 (depends on 1)

A composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier, adjuvant, or vehicle.

### Claim 15 (depends on 1)

A method of inhibiting ROCK kinase activity in a biological sample comprising contacting said biological sample with a compound according to claim 1, or a pharmaceutical composition thereof.

### Claim 16 (depends on 14)

A method of treating or lessening the severity of glaucoma in a patient comprising the step of administering to said patient a therapeutically effective dose of a composition according to claim 14.
